Abciximab (AX)
Abciximabis a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor. Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated coronary artery revascularization in the first month following the procedure. Research also shows that this drug can be of use for patients with diabetes and chronic renal insufficiency. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Abciximab (AX) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Abciximab (AX) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Abciximab (AX) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Abciximab (AX) CLIA Kit Customized Service Offer
n/a ELISA Kit for Abciximab (AX) ELISA Kit Customized Service Offer